I. AMENDMENTS

This listing of claims replaces all prior versions and listings of the claims in the subject application:

Listing of Claims:

1. (Currently Amended) A method for determining if ~~of aiding in the diagnosis of a neoplastic condition of~~ a lung cell isolated from a patient has neoplastic potential, comprising detecting the presence of the ~~an~~ overexpressed proto-oncogene PGP9.5 ~~,~~ in a the lung cell ~~sample,~~ wherein the overexpression is indicative of the neoplastic potential ~~condition~~ of the lung cell.

2. (Withdrawn) The method of claim 1, wherein the proto-oncogene is b-myb.

3. (Canceled).

4. (Withdrawn) The method of claim 1, wherein the proto-oncogene is 8-oxo-dGTPase.

5. (Withdrawn) The method of claim 1, wherein the proto-oncogene is p67.

6. (Withdrawn) The method of claim 1, wherein the presence of the overexpressed proto-oncogene is determined by detecting the quantity of mRNA transcribed from the proto-oncogene.

7. (Withdrawn) The method of claim 2, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TGCTGCCCTG (SEQ. ID No.1) or its complement.

8. (Withdrawn) The method of claim 3, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence is CAGTCTAAAA (SEQ. ID No.2) or its complement.

9. (Withdrawn) The method of claim 4, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TGGCCCGACG (SEQ. ID No.3) or its complement.

10. (Withdrawn) The method of claim 5, wherein the detecting is determined by probing the sample with a probe or primer comprising the sequence TAATACTTTT (SEQ ID NO. 4) or its complement.

11. (Withdrawn) The method of claim 6, wherein the presence of the overexpressed proto-oncogene is determined by detecting the quantity of cDNA produced from the reverse transcription of the mRNA.

12. (Previously Presented) The method of claim 1, wherein the presence of the overexpressed proto-oncogene PGP9.5 is determined by detecting the quantity of the polypeptide or protein encoded by the proto-oncogene.

13. (Canceled)

14. (Withdrawn) A screen for a potential therapeutic agent for the reversal of the neoplastic condition of a lung cell wherein the cell is characterized by overexpression of a proto-oncogene selected from the group consisting of b-myb, p67, PGP9.5 and 8-oxo-dGTPase comprising contacting a sample with an effective amount of a potential agent and assaying for reversal of the neoplastic condition.

15. (Withdrawn) The screen of claim 14, wherein the proto-oncogene is b-myb.

16. (Withdrawn) The method of claim 14, wherein the proto-oncogene is PGP9.5.

17. (Withdrawn) The method of claim 14, wherein the proto-oncogene is 8-oxo-dGTPase.

18. (Withdrawn) The method of claim 14, wherein the proto-oncogene is p67.

19. (Withdrawn) A method for reversing the neoplastic condition of a lung cell, wherein the cell is characterized by overexpression of a proto-oncogene comprising contacting the cell with an agent identified by the method of claim 14.

20. (Withdrawn) The method of claim 19, wherein the proto-oncogene is b-myb.

21. (Withdrawn) The method of claim 19, wherein the proto-oncogene is PGP9.5.

22. (Withdrawn) The method of claim 19, wherein the proto-oncogene is 8-oxo-dGTPase.

23. (Withdrawn) The method of claim 19, wherein the proto-oncogene is p67.

24. (Withdrawn) The method of claims 19, wherein the agent is anti-sense RNA that specifically inhibits the overexpression of the proto-oncogene.

25. (Withdrawn) A probe or primer to detect the presence of b-myb, comprising sequence TGCTGCCCTG (SEQ. ID No.1) or its complement.

26. (Withdrawn) A probe or primer to detect the presence of PGP9.5, comprising sequence CAGTCTAAAA (SEQ. ID No.2) or its complement.

27. (Withdrawn) A probe or primer to detect the presence of 8-oxo-dGTPase, comprising sequence TGGCCCGACG (SEQ. ID No.3) or its complement.

28. (Withdrawn) A probe or primer to detect the presence of p67, comprising sequence TAATACTTTT (SEQ ID NO. 4) or its complement.

29. (Withdrawn and Currently Amended) A solid phase support comprising the probes or primers of claim 25 or their complements.

30. (Withdrawn) A kit for use in a diagnostic method according to claim 1 comprising in suitable packaging: one or more polynucleotides selected from the group consisting of b-myb, p67, PGP9.5 and 8-oxo-dGTPase immobilized on a solid support and a reagent suitable for hybridizing a sample suspected of containing the lung cancer cell.

31. (New) The method of claim 1, wherein neoplastic potential is to non-small cell lung cancer.

32. (New) The method of claim 1, wherein the neoplastic potential of the lung cell is independent of neuroendocrine features of the cell.

33. (New) The method of claim 1, wherein the neoplastic potential further comprises metastatic potential.